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Background: To identify published letters to the editor (LTE) written in response to randomized controlled trials
(RCTs), determine the topics addressed in the letters, and to examine if these topics were affected by the
characteristics and results of the RCTs.
Methods: Comparative cross-sectional study of a representative sample of RCTs from a set of high-impact medical
journals (BMJ, Lancet, NEJM, JAMA, and Annals of Internal Medicine). RCTs and their published LTE were searched
from these 5 journals in 2007. Data were collected on RCTs and their characteristics (author affiliation, funding
source, intervention, and effect on the primary outcome) and the topics addressed in published LTE related to
these RCTs. Analysis included chi-square and regression analysis (RCT characteristics) and thematic analysis
(LTE topics).
Results: Of 334 identified RCTs, 175 trials had at least one LTE. Of these, 381 published LTE were identified. Most
RCTs, tested drug interventions (68%), were funded by government (54%) or industry (33%), and described an
intervention that had a positive impact on the primary outcome (62%). RCT authors were primarily affiliated with an
academic centre (78%). Ninety percent of the 623 LTE topics concerned methodological issues regarding the
analysis, intervention, and population in the RCT. There was a significant association between funding source and
impact on outcomes (p = 0.002) or type of intervention tested (p = 0.001) in these trials. Clinical and “Other” LTE
topics were more likely to be published in response to a government funded RCT (p = 0.005 and p = 0.033,
respectively); no other comparisons were significant.
Conclusions: This study showed that most LTE are about methodological topics, but found little evidence to
support that these topics are affected by the characteristics or results of the RCTs. The lack of association may be
explained by editorial censorship as a small proportion of LTE that are submitted are actually published.
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Published letters to the editor (LTE) are short communi-
cations that report study data or more often provide
viewpoints that support or challenge a published paper.
LTE have also been used to teach critical appraisal skills
for medical students [1] and to enhance the educational
value of journal clubs [2]. They are considered a form of
post-publication peer review and an essential part of* Correspondence: monika.kastner@utoronto.ca
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reproduction in any medium, provided the orscientific debate [3-7]. LTE provide a platform to com-
ment on, clarify and correct published research by
alerting readers about aspects of a paper that may have
been overlooked by authors, peer-reviewers and editors
[5-8]. Some authors have argued that an article is not
fully peer-reviewed until after publication [9,10] and that
authors of LTE may have more credibility than pre-
publication peer reviewers because their opinions are
signed, published and thus transparent [3].
However there is some skepticism regarding the repre-
sentativeness of opinions expressed in published LTE
[4-6] (for example, do the statements reflect a generalLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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peutic area or a suggestion pertaining to the study
methods?). Little is known about the topics commonly
addressed in LTE and whether these topics are
influenced by characteristics of the randomized con-
trolled trial (RCT) (e.g. positive/negative outcomes, pres-
ence of serious harm, type of intervention, author
affiliation, funding source, etc.). For example, LTE topics
may represent opinions that are partially based on
whether the RCT reported positive or negative results
for the primary outcome. LTE topics may also be
influenced by whether an RCT was financially supported
by a government body, an academic institution or drug
industry. For example, a negative trial of a new drug
funded by a peer national granting agency may lead
those with a vested interest in the outcome (e.g. com-
pany employees, academics whose careers are vested in
the drug) to write negative comments about the meth-
odology of the trial, which they might not have done
had the trial results been positive. The primary objec-
tives of this empirical study were 1) to identify the types
of topics addressed in published LTE for a sample of
RCTs, and 2) to examine if these topics were affected by
characteristics of the RCTs.
Methods
Using a quantitative cross-sectional design, we used a
representative sample of 5 high impact general medical
journals that publish methodologically rigorous RCTs
(BMJ, Lancet, NEJM, JAMA, and Annals of Internal
Medicine), to consecutively select RCTs with published
LTEs from each journal’s on-line websites (except for
rapid responses published by BMJ) for a period of one
year beginning with the first issue in January 2006. It
was not possible to perform a formal sample size calcu-
lation, as there is insufficient evidence to estimate a
magnitude of the expected difference in our outcome.
However, based on a study with similar methods to
investigate the content of LTE [11] (and given that our
study was exploratory), we estimated that a sample size
of approximately 200 published RCTs with at least one
LTE would identify the majority of reasons published
LTE are written, and allow for a statistical estimation of
the relative frequency of these reasons. We considered
only online-published LTE in our sample. To ensure that
we captured all published LTE related to their trial to
which they pertained, we estimated the publication time
period for these letters by analyzing a sample set of 10
RCTs (2 from each journal) and their time to published
LTE. We found that responses appeared 3-8 months
after the publication of the original RCT, so we selected
RCTs published at least one year prior to the beginning
of our study period of 2007 (i.e., we searched for RCTs
published in 2006). We performed the search for RCTsand their corresponding LTE in PubMed by “AND-ing”
each of the 5 journals with the publication year of 2006
(e.g., “Lancet[Jour] AND 2006[pdat]). These yields were
then filtered by AND-ing them with the term: “rando-
mized controlled trial”. One reviewer scanned search
yields for RCTs with at least one LTE. If no LTE was
listed, we entering the RCT citation information in the
“single citation matcher” feature of PubMed interface
(http://www.ncbi.nlm.nih.gov/pubmed/citmatch) to verify
if any correspondence related to the original RCT was
available and accessible via hyperlinks.
Data collection and outcomes
RCTs: The following data were extracted from RCTs: the
first author and their affiliation, funding source, the
characteristics of the intervention (drug, other), and the
results (effect upon the primary outcome and harms).
Two researchers (MK & AM) abstracted data and classi-
fied the trial results independently using a combination
of assessment of the benefits and harms and the inter-
pretation of the results as provided and interpreted by
the authors of the RCT. RCTs were divided into the
following categories: positive impact upon primary out-
come (i.e., intervention significantly better than control
according to thresholds set by authors) and serious
harms or no serious harms; negative impact upon the
primary outcome (i.e., intervention is significantly worse
than control); no impact upon the primary outcome (i.e.,
intervention neither better nor worse than control) and
serious harms or no serious harms. Harms were
recorded based on what authors reported in the results
and discussion section of their paper. The purpose of
this investigation was to identify any possible associa-
tions between the outcomes of the RCT and the topic(s)
of the LTE that was written in response.
Letters to the Editor: We extracted data from pub-
lished LTE including their topics and objectives, and
how these themes related to the design and results of
the RCT. Three broad topic categories were identified a
priori by the research team: Methodological (topics rela-
ted to the RCT’s study design, outcomes, population,
intervention, and analysis); clinical (topics describing
biological mechanisms, diagnosis, and treatment of the
clinical area); and “other” (any aspect of the RCT not
related to methodological or clinical topics).
Analysis
Descriptive statistics were used to determine 5 RCT char-
acteristics: impact on primary outcomes (positive, negative,
none), presence of serious harms (harm, no harm), type of
intervention tested (drug, other), author affiliation (i.e., aca-
demic centre, hospital, research institute, community prac-
tice/clinic, government, and industry), and funding source
(government, academic, industry, other, not indicated). We
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within each of the 5 journals. RCT-level comparisons were
analyzed using chi-square statistics to test associations
between the impact on outcomes reported in the RCT
(positive/negative/none) and its funding source; and the
type of intervention tested in the RCT (drug/other) and its
funding source using SPSS, version 17.0. All 5 RCT charac-
teristics were considered of similar importance in the
analysis. To account for RCTs with different numbers of
LTE, we used Poisson regression analysis to test LTE-level
comparisons. We tested associations between LTE topic
and the following RCT characteristics: impact of the inter-
vention on primary outcomes, presence of serious harm,
type of intervention, funding source, and author affiliation.
LTE topics were analyzed qualitatively using thematic
analysis, which involved two researchers (MK and AM)
independently classifying topics into 3 broad categories
(methodological, clinical, other), and then iteratively identi-
fying sub-categories and themes within these core catego-
ries. Two researchers (AL, SS) were consulted to resolve
conflicts, and to verify the appropriateness and relevance
of the final topic classifications and their labels.
Results
Searches in the 5 journals for the year 2007 identified
334 RCTs, of which175 trials had at least one published
LTE, generating a total of 381 published LTE (range 1-5
LTE per RCT) (Table 1). The NEJM had the highest
yield of RCTs (54%), LTE (61%), and topics (58%)
followed by JAMA, Lancet, BMJ, and Ann Int Med. Of
the 175 RCTs, 62% reported interventions that had a
positive impact on the primary outcome, and 92%
reported no statistically significant increase in adverse
events related to the intervention (as indicated by study
authors). Most RCTs (68%) were drug interventions,
54% of which were funded by government and 33% by
industry. Authors of the RCT were primarily affiliated
with an academic centre (78%).
Of 381 published LTEs, 623 topics were identified
(range 1-5 topics per LTE)—564 (90%) methodological,
42 (7%) clinical and 17 (3%) other. The Figure shows







NEJM 94 (54) 233 (61) 359 (58)
JAMA 35 (20) 56 (15) 108 (17)
Lancet 27 (15) 60 (16) 110 (18)
BMJ 11 (6) 19 (5) 26 (4)
AnnIntMed 8 (5) 13 (3) 20 (3)
TOTAL 175 381 623
*RCT = randomized controlled trial; LTE = letter to the editor.methodological theme were grouped into a number of
categories such as statistical analysis, results, discussion,
and generalizability (Figure 1). Clinical topics represented
opinions or comments about medical procedures, clinical
practice issues, costs (e.g., medications, resources), clinical
outcomes, and topics related to “surprising” or unexpec-
ted results or recommendations for conducting future
studies to verify results. Topics in the “Other” category
comprised conflict of interest (i.e., industry sponsorship,
publication bias, and failure of contributor(s) to disclose
information), ethical issues, criticisms of an accompanying
editorial, and non-clinical opinions.
Ninety percent of the topics discussed in LTE were
methodological; most addressed the analysis (40%),
intervention (21%), and population (13%) (Table 1).
Sixty-one percent of letters about clinical themes were
about clinical opinions (e.g., “A double standard clearly
exists among the screening community, who seem to be in
denial - the problem of over-diagnosis that was finally
confirmed by irrefutable evidence in the study can no
longer be denied”). In the “Other” category, 41% of LTE
topics were related to ethical issues (e.g., “Study patients
should not pay for trial medications and we are sur-
prised that the local ethics committee ignored this fact”);
29% were about conflict of interest (e.g., “One of the
principal contributors fails to declare a given conflict of
interest which can be found in a Cochrane review”); and
29% were about a criticism of an accompanying editorial
(e.g., “…The statement in the accompanying editorial
that the results of the author are not likely to influence
current clinical practice is perplexing”).
RCT-level comparisons
A significant association between funding source and
the impact of the intervention on outcomes in the RCTs
(p = 0.002) was found. Of 108 RCTs with a positive im-
pact on outcomes, 44% were funded by government, 40%
by industry, 7% by academic, and 4% by other (5% did not
indicate); “no impact” RCTs (N = 58) were primarily
funded by government (78%), while about half of the
negative impact trials (N = 9) were funded by industry
(56%). There was also a statistically significant associations by journal*
of
)
Categories of LTE topics (N = 623) (%)
Methodological Clinical Other
325 (58) 26 (62) 8 (47)
107 (19) 0 (0) 1 (6)
95 (17) 7 (17) 8 (47)
18 (3) 8 (19) 0 (0)
19 (3) 1 (2) 0 (0)
564 (91) 42 (7) 17 (3)
Figure 1 Classification of LTE topics according to three broad categories (Methodological, Clinical, Other).
Kastner et al. BMC Research Notes 2013, 6:414 Page 4 of 7
http://www.biomedcentral.com/1756-0500/6/414
Kastner et al. BMC Research Notes 2013, 6:414 Page 5 of 7
http://www.biomedcentral.com/1756-0500/6/414between funding source and the type of intervention
(p = 0.001). Most drug intervention RCTs (N = 119)
were funded by government (49%) or industry (42%),
while “other” intervention RCTs (N = 56) was funded
mostly by government (66%). Industry-funded RCTs
(N = 56) tested more drug interventions than government-
funded RCTs (N = 95) (89% vs 61%; p = 0.001 [Pearson
Chi-square 19.86]). No statistically significant associations
were found for other RCT-level comparisons such as
impact of primary outcome or type of intervention tested
and author affiliation. Please see Additional file 1: Table
S1 for additional data on the proportion of RCTs accor-
ding to impact on primary outcome and type of interven-
tion by funding source.
LTE-level comparisons
Of the LTE addressing methodological topics, 54% were in
response to government-funded RCTs and 32% responded
to industry-funded RCTs. Letters about clinical or otherTable 2 RCT characteristics and LTE-level comparisons*
RCT characteristic Number of Top
(Number of RCTs; N = 175) Method (N = 564) Clinical (N
Impact on outcomes reported in the RCT
Positive (N = 108) 348 (62) 29 (69)
Negative (N = 9) 28 (5) 5 (12)
None (N = 58) 188 (33) 8 (19)
Presence of serious harm in outcomes of the RCT
Harm (N = 161) 502 (89) 36 (86)
No harm (N = 4) 62 (11) 6 (14)
Type of intervention tested in the RCT
Drug (N = 119) 392 (70) 27 (64)
Other (N = 56) 172 (30) 15 (36)
Author affiliation of the RCT
Academic (N = 137) 438 (78) 32 (76)
Hospital (N = 26) 94 (17) 7 (17)
Research Institute (N = 6) 15 (2) 1 (2)
Community practice (N = 3) 10 (1.8) 0 (0)
Government (N = 2) 6 (1) 0 (0)
Industry (N = 1) 1 (0.2) 2 (5)
Funding source of the RCT
Government (N = 95) 303 (54) 23 (55)
Academic (N = 9) 30 (5) 3 (7)
Industry (N = 56) 178 (32) 6 (14)
Other (N =7) 12 (2) 4 (10)
Not indicated (N = 8) 41 (7) 6 (14)
*RCT = randomized controlled trial; Method. = Methodological; LTE = letter to the ed
†Calculated using Poisson Regression analysis.
‡Significant at p < 0.05.topics were mostly about RCTs funded by government
(55%, 52%, respectively). Poisson regression analysis
showed a statistically significant association between RCT
funding source and topic of the LTE (p = 0.002), indicating
that clinical and “other” LTE topics were more likely to be
published in response to a government funded RCT
(p = 0.005 and p = 0.033, respectively). Table 2 shows
the differences between the remainder of RCT charac-
teristics (impact on outcome, presence of serious
harm, type of intervention, and author affiliation) and
LTE topics—none of these were significant. Please see
Additional file 1: Table S2 for additional data on the pro-
portion of LTE themes by funding source of the RCT.
Discussion
We conducted a descriptive study to identify topics
addressed in LTEs of published RCTs, and whether these
topics may be affected by characteristics of the RCTs to
which they refer. Analysis of 175 RCTs with correspondingics (%) P-value† RCT characteristic
compared with LTE topic:
Methodological, Clinical or Other
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the majority of RCTs reported a positive impact on
the primary outcome, with 38% reporting no impact
or negative impact on primary outcomes. The major-
ity of published LTE focused on methodological
aspects of the RCT specific to its analysis, interven-
tion and population (Table 3). These results support
the idea that LTEs can be used as a form of post-
publication peer review and that they can play an
important role in identifying potential methodological
flaws [7,12]. However, only a small proportion of
articles undergo substantive criticism in LTE (e.g., a
problem that suggest fatal flaws in the design that
could invalidate the research) [4,12]. Gotzsche et al
found that although 88% of rapid responses were
available for research papers submitted to the BMJ,
only 30% raised substantive criticism, of which only
19% were published in the print version of the jour-
nal [4]. Baethge et al conducted a search in Medline
in 2007, and found that only 15,312 letters and com-
ments were generated from a total of 117,843 original
published clinical articles and reviews [12]. Further-
more, criticisms are often ignored and undervalued
by researchers and clinicians even though they have
the potential to shape clinical knowledge [4,6,7]. This
work also highlights the potential for LTE to be used
as a unique knowledge translation tool for journal
readers (clinicians and researchers) and editors. For
example, LTE could be used as a platform to advance
knowledge around research methods; clinical gaps and
clinical experiences (i.e., what works or doesn’t work
under different circumstances); and to provide the op-
portunity to share/suggest ideas, research questions or
next steps by fostering collaborations across research
groups (and continents) to minimize redundancies
and duplication of efforts.
To our knowledge, this is the first study to investigate
the types of topics addressed in published LTE for a
sample of RCTs across 5 high impact journals, and to
test the association between the outcomes of the RCT
and the topic(s) of the LTE that was written in response
to the RCT. There are some limitations to this study.
We searched only 5 medical journals, so our sample sizeTable 3 Number of letters according to sub-categories of met
Journal Study design Outcomes Population Intervention
NEJM 30 14 50 72
JAMA 9 6 15 19
Lancet 6 6 10 19
BMJ 1 3 0 3
AnnIntMed 2 1 0 8
TOTAL 48 (9) 30 (5) 75 (13) 121 (21)may have been too small to detect significant differences.
However, we included the journals that publish a large
proportion of methodologically rigorous randomized
trials, which likely maximized the number of LTE and
the breadth (reaching researchers as well as clinicians)
and depth (more focused and detailed discussions) of
topics. Our focus on high-impact journals may have also
biased the ‘type’ of scrutiny provided by their letters
compared with those published in lower impact journals
—an important consideration if LTE are used for the
purposes of post-publication peer review. Indeed, LTE
addressing methodological topics might be more often
reported in lower impact journals. In addition, not all
letters submitted to these journals get published, and we
did not account for the balance of RCTs published
across journals (i.e., some publish more trials per issue
than others), so the frequency of topics we identified
may not be an accurate representation of all the is-
sues raised by LTE. Furthermore, we did not compare
RCT characteristics between studies that generated a
letter with those that did not – this information may
have strengthened our findings and is a potential
topic for a future study. Another limitation is that we
may have also missed some letters that could have
been published beyond our predicted 1-year period.
However, it is unlikely that a small number of add-
itional letters would have influenced our findings.
Finally, analysis of all letters submitted to journals
(not just the ones published by journals or those ac-
cessible electronically) may have also increased our
power to detect differences.
Conclusions
The study found little evidence that LTE topics are
affected by the characteristics or results of their corre-
sponding RCTs. However, some letters that are submit-
ted do not get published, so these findings may in part
reflect editorial censorship as journal editors make the
final decision on LTE publications. Our findings also
showed that most LTEs from 5 high-impact medical
journals are about methodological topics, which may
indicate a potential for LTE to be used as a form of
post-publication peer review.hodological themes by journal
Analysis Results Discussion Generalizability TOTAL
130 5 9 15 325 (58)
46 0 2 10 107 (19)
38 4 6 6 95 (17)
7 1 1 2 18 (3)
4 0 3 1 19 (3)
225 (40) 10 (2) 21 (4) 34 (6) 564
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